Supernus Pharmaceuticals
Open
$44.34
Prev. Close
$44.35
High
$44.49
Low
$44.33
Market Snapshot
$2.56B
-88.1
1.34
$661.82M
778
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. The company is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The company focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. The company is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.
Recently from Cashu
Supernus Pharmaceuticals Reports Strong Q4 Earnings and Optimistic Growth Outlook for 2026
Supernus Pharmaceuticals: A Strong Performance Drives Future Growth Outlook Supernus Pharmaceuticals announces its Q4 earnings results for 2026, showcasing impressive financial performance that reinfo…
Supernus Pharmaceuticals Reports Strong Q4 Earnings and Ambitious Growth Plans for 2027
Supernus Pharmaceuticals Achieves Strong Q4 Earnings and Signals Ambitious Growth Plans Supernus Pharmaceuticals, a company renowned for its innovative treatments in the neurological space, announces…
Supernus Pharmaceuticals Positioned for Growth with Strong Analyst Backing and Innovative Treatments
Supernus Pharmaceuticals: A Rising Star in the Pharmaceutical Sector Supernus Pharmaceuticals is gaining recognition for its potential growth as it attracts attention from analysts, particularly Bank…
Supernus Pharmaceuticals Enhances Neurological Disorder Treatments with Promising Pipeline and Collaborations
Supernus Pharmaceuticals Advances Treatment Options for Neurological Disorders Supernus Pharmaceuticals, a key player in the development of innovative therapies for central nervous system (CNS) disord…